These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21743488)

  • 1. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.
    Pradeep CR; Köstler WJ; Lauriola M; Granit RZ; Zhang F; Jacob-Hirsch J; Rechavi G; Nair HB; Hennessy BT; Gonzalez-Angulo AM; Tekmal RR; Ben-Porath I; Mills GB; Domany E; Yarden Y
    Oncogene; 2012 Feb; 31(7):907-17. PubMed ID: 21743488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
    Shekhar MP; Kato I; Nangia-Makker P; Tait L
    Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
    Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
    Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
    Horimoto Y; Terao T; Tsutsumi Y; Tanabe M; Mogushi K; Hlaing MT; Sasaki R; Saeki H; Okazaki M; Sonoue H; Arakawa A; Saito M
    Am J Surg Pathol; 2019 Sep; 43(9):1221-1228. PubMed ID: 31192864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
    Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
    J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Pradeep CR; Zeisel A; Köstler WJ; Lauriola M; Jacob-Hirsch J; Haibe-Kains B; Amariglio N; Ben-Chetrit N; Emde A; Solomonov I; Neufeld G; Piccart M; Sagi I; Sotiriou C; Rechavi G; Domany E; Desmedt C; Yarden Y
    Oncogene; 2012 Aug; 31(31):3569-83. PubMed ID: 22139081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus Inhibits the Progression of Ductal Carcinoma
    Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
    Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β1-Integrin via NF-κB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer.
    Nam JM; Ahmed KM; Costes S; Zhang H; Onodera Y; Olshen AB; Hatanaka KC; Kinoshita R; Ishikawa M; Sabe H; Shirato H; Park CC
    Breast Cancer Res; 2013; 15(4):R60. PubMed ID: 23883667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
    Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
    Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer.
    Rossetti S; Bshara W; Reiners JA; Corlazzoli F; Miller A; Sacchi N
    Cancer Lett; 2016 Oct; 380(2):375-383. PubMed ID: 27422542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
    Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
    Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.
    Valdez KE; Fan F; Smith W; Allred DC; Medina D; Behbod F
    J Pathol; 2011 Dec; 225(4):565-73. PubMed ID: 22025213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.
    Yamaguchi N; Oyama T; Ito E; Satoh H; Azuma S; Hayashi M; Shimizu K; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Ohwada S; Tatsuta K; Inoue J; Semba K; Watanabe S
    Cancer Res; 2008 Mar; 68(6):1881-8. PubMed ID: 18339869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.